Clinical Trials Logo

Clinical Trial Summary

This research study is evaluating the impact a collaborative palliative care and oncology team will have on the quality of life, symptoms, mood, and end of life outcomes of patients with acute myeloid leukemia (AML). Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.


Clinical Trial Description

The main purpose of this study is to compare two types of care - standard leukemia oncology care and standard leukemia oncology care with collaborative involvement of palliative care clinicians to see which is better for improving the experience of patients and families with AML undergoing treatment.

The investigators aim to find out whether introducing patients and families undergoing AML treatment to the palliative care team that specializes in symptom management can improve the physical and psychological symptoms that patients and families experience during their hospitalizations for their leukemia care as well as enhance the quality of patients' end of life care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02975869
Study type Interventional
Source Massachusetts General Hospital
Contact Areej El-Jawahri, MD
Phone 617-643-4003
Status Recruiting
Phase N/A
Start date September 2016
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Recruiting NCT03224819 - Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Early Phase 1
Active, not recruiting NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Recruiting NCT02882321 - Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT03214562 - Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Recruiting NCT03298984 - Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). Phase 1
Recruiting NCT03256071 - Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT Phase 2/Phase 3
Recruiting NCT02909972 - Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Phase 1
Recruiting NCT02668653 - Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) Phase 3
Recruiting NCT02708641 - A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML Phase 2
Active, not recruiting NCT02899286 - Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Recruiting NCT02400255 - Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients Phase 2
Recruiting NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Recruiting NCT02400281 - Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Phase 1/Phase 2
Recruiting NCT02483312 - A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) Phase 1
Recruiting NCT02229266 - Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML Phase 2
Recruiting NCT02502968 - BL-8040 Addition to Consolidation Therapy in AML Patients Phase 2
Completed NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT02113982 - SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Phase 1/Phase 2